Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

20.65 +0.18 (+0.88%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,077,184
Open 20.61
Bid (Size) 20.65 (5)
Ask (Size) 23.22 (1)
Prev. Close 20.47
Today's Range 20.59 - 20.84
52wk Range 20.34 - 32.88
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
NASDAQ:GMAB, a growth stock which is not overvalued. 
Via Chartmill
A Closer Look at 10 Analyst Recommendations For Genmab
Via Benzinga

Performance

YTD
-35.69%
-35.69%
1 Month
-9.51%
-9.51%
3 Month
-24.52%
-24.52%
6 Month
-26.28%
-26.28%
1 Year
-34.69%
-34.69%

More News

Read More
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
From Genmab A/S
Via Business Wire
Preview: Genmab's Earnings
Via Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Via Chartmill
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
12 Analysts Have This To Say About Genmab
Via Benzinga
NASDAQ:GMAB qualifies as a high growth stock and is consolidating.
Via Chartmill
NASDAQ:GMAB is an undervalued gem with solid fundamentals.
Via Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via Chartmill
NASDAQ:GMAB, a growth stock which is not overvalued.
Via Chartmill
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
Via Chartmill
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
From Genmab A/S
Via Business Wire
Expert Ratings For Genmab
Via Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Via Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
Decoding 10 Analyst Evaluations For Genmab
Via Benzinga
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Genmab Announces Changes to its Executive Committee
From Genmab A/S
Via Business Wire
On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
Via Benzinga
GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
Via Benzinga
Exposures COVID-19
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.